Silence Therapeutics PLC Corporate Call Transcript
(technical difficulty)
Dr. Tom Ganz from the David Geffen School of Medicine at UCLA, who will discuss the key role of hepcidin in iron regulation and its therapeutic potential. From our London site, we have our Head of R&D and Chief Medical Officer; Dr. Giles Campion, who will provide an update on our SLN124 hepcidin regulation program.
Additionally, we are excited to have Dr. Henry Ginsberg, Irving Professor of Medicine at Columbia University College of Physicians and Surgeons. Dr. Ginsberg will share an overview of the medical need in cardiovascular disease. Following his presentation, Giles will give an update on our SLN360 program for cardiovascular disease due to high lipoprotein(a). Mark will then provide some concluding remarks and moderate a Q&A session at the end of the meeting or at the end of the presentation.
If you would like to submit a question, you can do so at any time during the meeting by typing your questions in the Ask a Question field on the right side of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |